LncRNA miR503HG Regulates the Drug Resistance of Recurrent Cervical Squamous Cell Carcinoma Cells by Regulating miR-155/Caspase-3
Authors Zhao S, Yu M, Wang L
Received 31 July 2019
Accepted for publication 5 February 2020
Published 3 March 2020 Volume 2020:12 Pages 1579—1585
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Bilikere Dwarakanath
Shanshan Zhao, Mingxin Yu, Lei Wang
Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Gynaecology, Shenyang 110042, Liaoning Province, People’s Republic of China
Correspondence: Mingxin Yu
Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Gynaecology, No. 44 Xiaoheyan Road, Dadong District, Shenyang 110042, Liaoning Province, People’s Republic of China
Tel +86 138 4033 2413
Introduction: The purpose of this study is to investigate the role of long non-coding RNA (lncRNA) miR503 Host Gene (miR503HG) in cervical squamous cell carcinoma (CSCC).
Methods: Analysis of TCGA dataset revealed that expression levels of miR503HG in CSCC tissues were over 12 times lower than those in non-tumor tissues, indicating its involvement in CSCC.
Results: In this study, we observed that levels of miR503HG in plasma were significantly lower in CSCC patients than in healthy participants. The cisplatin-based treatment further downregulated miR503HG in both patients and CSCC cells. MiR503HG overexpression in CSCC cells led to the suppression of miR-155 and elevation of Caspase-3, acting as the downstream target of miR-155. Cell apoptosis analysis showed that miR503HG and Caspase-3 overexpression led to an increased cell apoptosis rate under Cisplatin treatment. MiR-155 played the opposite role and attenuated the functions of Caspase-3 and miR503HG overexpression.
Conclusion: Therefore, miR503HG may regulate the drug resistance of CSCC cells by regulating mir-155/Caspase-3.
Keywords: cervical squamous cell carcinoma, miR503HG, miR-155, Caspase-3, apoptosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]